Vanoxerine free base

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 504510

CAS#: 67469-69-9 (free base)

Description: Vanoxerine, also known as GBR-12909; I-893, is a dopamine ruptake inhibitor potentially for the treatment of atrial fibrillation.

Chemical Structure

img
Vanoxerine free base
CAS# 67469-69-9 (free base)
Instruction

Theoretical Analysis

MedKoo Cat#: 504510
Name: Vanoxerine free base
CAS#: 67469-69-9 (free base)
Chemical Formula: C28H32F2N2O
Exact Mass: 450.25
Molecular Weight: 450.560
Elemental Analysis: C, 74.64; H, 7.16; F, 8.43; N, 6.22; O, 3.55

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 67469-69-9 (free base)   67469-78-7 (HCl)    

Synonym: Vanoxerine; GBR-12909; GBR12909; GBR 12909; I-893; I 893; I893.

IUPAC/Chemical Name: 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine

InChi Key: NAUWTFJOPJWYOT-UHFFFAOYSA-N

InChi Code: InChI=1S/C28H32F2N2O/c29-26-12-8-24(9-13-26)28(25-10-14-27(30)15-11-25)33-22-21-32-19-17-31(18-20-32)16-4-7-23-5-2-1-3-6-23/h1-3,5-6,8-15,28H,4,7,16-22H2

SMILES Code: FC1=CC=C(C(C2=CC=C(F)C=C2)OCCN3CCN(CCCC4=CC=CC=C4)CC3)C=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >5 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info: Related CAS# 67469-69-6 (Vanoxerine) 67469-78-7 (Vanoxerine Hydrochloride)

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 450.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Cakulev I, Lacerda AE, Khrestian CM, Ryu K, Brown AM, Waldo AL. Oral vanoxerine prevents reinduction of atrial tachyarrhythmias: preliminary results. J Cardiovasc Electrophysiol. 2011 Nov;22(11):1266-73. doi: 10.1111/j.1540-8167.2011.02098.x. Epub 2011 May 26. PubMed PMID: 21615815; PubMed Central PMCID: PMC3172341.

2: Matsumoto N, Khrestian CM, Ryu K, Lacerda AE, Brown AM, Waldo AL. Vanoxerine, a new drug for terminating atrial fibrillation and flutter. J Cardiovasc Electrophysiol. 2010 Mar;21(3):311-9. Epub 2009 Oct 8. PubMed PMID: 19817929.

3: Lacerda AE, Kuryshev YA, Yan GX, Waldo AL, Brown AM. Vanoxerine: cellular mechanism of a new antiarrhythmic. J Cardiovasc Electrophysiol. 2010 Mar;21(3):301-10. Epub 2009 Oct 8. PubMed PMID: 19817928; PubMed Central PMCID: PMC3107714.

4: Cherstniakova SA, Bi D, Fuller DR, Mojsiak JZ, Collins JM, Cantilena LR. Metabolism of vanoxerine, 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine, by human cytochrome P450 enzymes. Drug Metab Dispos. 2001 Sep;29(9):1216-20. PubMed PMID: 11502731.

5: Preti A. Vanoxerine National Institute on Drug Abuse. Curr Opin Investig Drugs. 2000 Oct;1(2):241-51. PubMed PMID: 11249581.

6: Ingwersen SH, Snel S, Mant TG, Edwards D. Nonlinear multiple-dose pharmacokinetics of the dopamine reuptake inhibitor vanoxerine. J Pharm Sci. 1993 Nov;82(11):1164-6. PubMed PMID: 8289134.

7: Ingwersen SH, Mant TG, Larsen JJ. Food intake increases the relative oral bioavailability of vanoxerine. Br J Clin Pharmacol. 1993 Mar;35(3):308-10. PubMed PMID: 8471409; PubMed Central PMCID: PMC1381581.

8: Ingwersen SH. Column liquid chromatographic assay of the dopamine reuptake inhibitor vanoxerine (GBR 12909) in human serum. J Chromatogr. 1991 Nov 15;571(1-2):305-11. PubMed PMID: 1839795.